Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;12(2):57-64.
doi: 10.1016/j.prnil.2023.11.004. Epub 2023 Dec 2.

Risks and side effects in the medical management of benign prostatic hyperplasia

Abdulghafour Halawani  1   2 , Ryan Paterson  2 , Tianshuang Zhong  2 , Katie Du  3 , Runhan Ren  2 , Connor M Forbes  2   4
Affiliations
Review

Risks and side effects in the medical management of benign prostatic hyperplasia

Abdulghafour Halawani et al. Prostate Int. 2024 Jun.

Abstract

Benign prostatic hyperplasia affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life. Lifestyle modifications and pharmacotherapy are often offered as first-line treatments for patients. These include alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, anticholinergics, B3-agonists, and desmopressin. While often well tolerated, these pharmacotherapies do have significant side effects, which both clinicians and patients should understand and discuss in order to make an informed treatment decision among alternatives. The purpose of this review is to provide a current overview of the risks and side effects of commonly used medications in benign prostatic hyperplasia management.

Keywords: Alpha-1 antagonists; Lower urinary tract symptoms; Medications; Prostatic Hyperplasia; Side effects; Treatmetn adverse events.

PubMed Disclaimer

Conflict of interest statement

None of the authors have conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13(1):20–33. - PMC - PubMed
    1. Marberger M. The MTOPS study: new findings, new insights, and clinical implications for the management of BPH. Eur Urol Suppl. 2006;5(9):628–633. doi: 10.1016/j.eursup.2006.05.002. - DOI
    1. Lerner L.B., McVary K.T., Barry M.J., Bixler B.R., Dahm P., Das A.K., et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. 2021;206(4):806–817. doi: 10.1097/JU.0000000000002183. - DOI - PubMed
    1. EAU guidelines on the management of non-neurogenic male LUTS – DISEASE MANAGEMENT – Uroweb. Uroweb – European Association of Urology. Accessed July 26, 2023. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/cha....
    1. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G., ARIA3001 ARIA3002 and ARIA3003 Study Investigators Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–441. doi: 10.1016/s0090-4295(02)01905-2. - DOI - PubMed

LinkOut - more resources